These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19229415)

  • 21. Paclitaxel-eluting stents for chronically occluded saphenous vein grafts (EOS) study.
    Jim MH; Ho HH; Ko RL; Siu CW; Yiu KH; Lau CP; Chow WH
    J Interv Cardiol; 2010 Feb; 23(1):40-5. PubMed ID: 20465719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Gordian knot of revascularization for multivessel coronary artery disease.
    Takagi H; Manabe H; Umemoto T
    J Thorac Cardiovasc Surg; 2011 Jul; 142(1):241-2; author reply 242-3. PubMed ID: 21683848
    [No Abstract]   [Full Text] [Related]  

  • 23. The SYNTAX trial: a perspective.
    Gulati R; Rihal CS; Gersh BJ
    Circ Cardiovasc Interv; 2009 Oct; 2(5):463-7. PubMed ID: 20031757
    [No Abstract]   [Full Text] [Related]  

  • 24. No evidence of "obesity paradox" after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry.
    Akin I; Tölg R; Hochadel M; Bergmann MW; Khattab AA; Schneider S; Senges J; Kuck KH; Richardt G; Nienaber CA;
    JACC Cardiovasc Interv; 2012 Feb; 5(2):162-9. PubMed ID: 22361600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus- vs. paclitaxel-eluting stents for the treatment of unprotected left main coronary artery stenosis: complete 2-year follow-up of a two-center registry.
    Park KW; Kang SH; Park KH; Choi DH; Lee HY; Kang HJ; Cho YS; Yeon TJ; Chung WY; Koo BK; Chae IH; Choi DJ; Oh BH; Park YB; Kim HS
    Int J Cardiol; 2011 Aug; 151(1):89-95. PubMed ID: 20605240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
    Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
    Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
    Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
    EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Each generation improves on the last (in cardiology): Bayesian thinking, the randomized clinical trial, and directed evolution.
    Morrison DA
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1018-9. PubMed ID: 21598353
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
    Grube E; Chevalier B; Smits P; Džavík V; Patel TM; Mullasari AS; Wöhrle J; Stuteville M; Dorange C; Kaul U;
    JACC Cardiovasc Interv; 2011 Feb; 4(2):168-75. PubMed ID: 21349455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.
    Qian J; Chen Z; Ma J; Ge J
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):507-13. PubMed ID: 22045690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in drug-eluting stents used in coronary artery disease.
    Synetos A; Toutouzas K; Karanasos A; Stathogiannis K; Triantafyllou G; Tsiamis E; Lerakis S; Stefanadis C
    Am J Med Sci; 2011 Nov; 342(5):402-8. PubMed ID: 21629039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A meta-analysis of randomized trials and adjusted observational studies of drug-eluting stents versus coronary artery bypass grafting for unprotected left main coronary artery disease.
    Takagi H; Umemoto T
    Int J Cardiol; 2011 Aug; 150(3):341-3. PubMed ID: 21636153
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-eluting stents for the treatment of acute myocardial infarction: the view to the HORIZONS.
    Prasad SB; Ahmar W; Malaiapan Y; Meredith IT
    Heart Lung Circ; 2010 Jan; 19(1):11-8. PubMed ID: 20022808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years.
    Serruys PW; Farooq V; Vranckx P; Girasis C; Brugaletta S; Garcia-Garcia HM; Holmes DR; Kappetein AP; Mack MJ; Feldman T; Morice MC; Ståhle E; James S; Colombo A; Pereda P; Huang J; Morel MA; Van Es GA; Dawkins KD; Mohr FW; Steyerberg EW
    JACC Cardiovasc Interv; 2012 Jun; 5(6):606-17. PubMed ID: 22721655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial.
    Cannon LA; Kereiakes DJ; Mann T; Popma JJ; Mooney MR; Mishkel GJ; Lee TC; Wilson BH; Stuckey TD; Orlow S; McGarry T; Ring ME; Kellett MA; Underwood P; Dawkins KD
    EuroIntervention; 2011 Mar; 6(8):920-7, 1-2. PubMed ID: 21330238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.